Ex vivo fermentation-guided dietary fiber personalization increases fecal volatile fatty acid production: a proof-of-concept crossover trial
Dietary fiber selection guided by individual ex vivo fermentation capacity (MyDFF platform) favored fecal volatile fatty acid production compared with non-personalized fiber, but complete quantitative data were not available in the provided text.
| Population | Adults with assessable gut microbiota, recruited at a single center at Kobe University, Japan |
|---|---|
| Intervention | Dietary fiber supplementation selected by the MyDFF ex vivo platform (the fiber yielding the highest individual fermentative VFA response) |
| Comparator | Dietary fiber supplementation not selected by the platform (non-personalized or crossover control fiber) |
| Outcome | Total fecal volatile fatty acid (VFA) production; Fecal butyrate production; Fecal acetate production; Fecal propionate production; Gut microbiota composition (diversity and taxonomy); Predictive validity of MyDFF ex vivo platform (ex vivo vs in vivo correlation) |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Total fecal volatile fatty acid (VFA) production | not reported in available text fragment | — | Low | — | 1 studies |
| Fecal butyrate production | not reported in available text fragment | — | Low | — | 1 studies |
| Fecal acetate production | not reported in available text fragment | — | Low | — | 1 studies |
| Fecal propionate production | not reported in available text fragment | — | Low | — | 1 studies |
| Gut microbiota composition (diversity and taxonomy) | not reported in available text fragment | — | Low | — | 1 studies |
| Predictive validity of MyDFF ex vivo platform (ex vivo vs in vivo correlation) | not reported in available text fragment | — | Low | — | 1 studies |
Context
SCFA production by gut microbiota varies substantially between individuals, making uniform fiber recommendations potentially ineffective. Taxonomic profiling alone does not reliably predict individual metabolic functional responses. This study tests whether prospective fiber selection based on ex vivo functional capacity outperforms a non-personalized approach.
What the study showed
The provided text corresponds predominantly to introduction and discussion sections, without complete numerical results tables. The reported direction of effect favors the personalized intervention for fecal VFA production. Absolute numbers, confidence intervals, and precise effect sizes could not be extracted from the available fragment. The trial was registered (jRCTs051220163) and uses a crossover design, implying intra-individual control.
How it was done
Proof-of-concept crossover clinical trial, Japanese registry jRCTs051220163, conducted at Kobe University. The MyDFF platform performs ex vivo fermentation of multiple fibers using individual fecal samples to prospectively identify the highest VFA-yielding fiber before in vivo intervention. Exact sample size and duration were not extractable from the provided text fragment.
Effect magnitude
Concrete effect size with 95% CI not available in the provided text fragment; the study is described as proof-of-concept, suggesting preliminary magnitude.
Risk of bias
Proof-of-concept design with presumably small sample limits statistical power and generalizability. Single center in Japan restricts applicability to populations with distinct microbiota. The text fragment does not allow formal bias risk assessment (RoB 2 for crossover RCTs); participant blinding is likely absent given the intervention type. The ex vivo platform may not faithfully replicate in vivo intestinal conditions.
What this study does NOT prove
This study does not prove that ex vivo personalization improves clinical health outcomes (only fecal VFAs as proxy). It is not generalizable to non-Japanese populations and does not establish causality between increased VFAs and clinical benefit.
In clinical practice
There is insufficient basis to recommend the MyDFF platform in routine clinical practice based on this single proof-of-concept trial. Clinicians should await larger, multicenter RCTs with diverse populations before adopting ex vivo screening for prebiotic selection. The study provides no guidance on which specific fiber benefits non-Japanese populations.
Limitations
Proof-of-concept design with presumably small sample limits statistical power and generalizability. Single center in Japan restricts applicability to populations with distinct microbiota. The text fragment does not allow formal bias risk assessment (RoB 2 for crossover RCTs); participant blinding is likely absent given the intervention type. The ex vivo platform may not faithfully replicate in vivo intestinal conditions.
What is still missing
Multicenter RCTs with larger samples and diverse populations are needed to validate the MyDFF platform. Relevant clinical outcomes (metabolic health, inflammatory markers, intestinal barrier function) must be evaluated beyond fecal VFAs.
Technical appendix
Version history
- 1.0 · 2026-10-20 — Auto-generated under Evidence Standard v1.0